Characterisation of Clinical Epidemiological Profie of Patients with Facial Lipoatrophy, Living with Aids, Submitted to Facial Filling with Polymethylmethacrylate

Abstract

Background : Patients living with AIDS and on Antiretroviral Therapy are likely to develop Lipodystrophy syndrome. Soft tissue filler with Polymethylmethacrylate is an option to treat Facial Lipoatrophy. It is a small procedure performed on an outpatient basis. Aimet to characterise the clinical and epidemiological profile of patients living with AIDS, who developed Facial Lipoatrophy and who underwent facial filler with Polymethylmethacrylate.Methods: A descriptive, observational study with 63 patients with AIDS, Facial Lipoatrophy, submitted to facial filling with Polymethylmethacrylate. As sources for data collection, data were analysed from records, and the Protocol Lipodystrophy Clinic of the Municipal STD/AIDS and Viral Hepatitis of São Bernardo do Campo, in São Paulo, Brazil, of patients treated between January and July 2009.Results: On average, HIV was diagnosed for 11.5 years, mean duration of antiretroviral therapy for 10 years and mean duration of 3.8 years for Facial Lipoatrophy. Most made use of Stavudine and/or Efavirenz. At the beginning of treatment, the mean dosage of CD4 was 284 cells/mm ³ and at the time of filling the average was 709 cells/mm³. Cholesterol levels were elevated in 44.4%, and the triglycerides were elevated in 66.7%. here were practically no adverse effects from the filling.Conclusion: On average, HIV was diagnosed for 11.5 years, mean duration of antiretroviral therapy for 10 years and mean duration of 3.8 years for Facial Lipoatrophy.Â